Advaxis, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2002-01-01

Employees: 51

Market Cap: $851.8K

Website: http://www.advaxis.com

Clinical Trials

Active:2

Completed:7

Trial Phases

3 Phases

Phase 1:8

Phase 2:5

Phase 3:2

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials

Phase 1

8 (53.3%)

Phase 2

5 (33.3%)

Phase 3

2 (13.3%)

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell
Metastatic Squamous Cell Carcinoma
Metastatic Non-Squamous Cell Carcinoma

Interventions: Drug: ADXS-503
Drug: Pembrolizumab

First Posted Date: 2019-02-20

Last Posted Date: 2024-06-04

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 24

Registration Number: NCT03847519

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 6 locations

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Phase 1

Terminated

Conditions: Head and Neck Cancer Metastatic
Urothelial Carcinoma
Metastatic Melanoma
Metastatic Non-Small Cell Lung Cancer
Colon Cancer Metastatic

First Posted Date: 2017-08-29

Last Posted Date: 2023-02-24

Lead Sponsor: Advaxis, Inc.

Target Recruit Count: 13

Registration Number: NCT03265080

Locations: 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Ochsner Clinic Foundation - Ochsner Cancer Institute, New Orleans, Louisiana, United States

and more 2 locations